4-aryl-4h-chromene-3-carbonitrile derivatives: Evaluation of Src kinase inhibitory and anticancer activities

Medicinal Chemistry

Volumn 7, Issue 5, 2011, Pages 466-472

  Fallah Tafti, Asal ^a   Tiwari, Rakesh ^b   Shirazi, Amir Nasrolahi ^b   Akbarzadeh, Tahmineh ^a   Mandal, Deendayal ^b   Shafiee, Abbas ^a   Parang, Keykavous ^b   Foroumadi, Alireza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Anticancer activity; Benzopyranones; Carbonitrile; Chromenes; Inhibitor; Protein kinase; Src kinase

Indexed keywords

2 AMINO 7 DIMETHYLAMINO 4H CHROMENE 3 CARBONITRILE DERIVATIVE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALDEHYDE; BOSUTINIB; CHROMENE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; MOLECULAR SCAFFOLD; PROTEIN TYROSINE KINASE; QUERCETIN; SARACATINIB; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HT29; COLON ADENOCARCINOMA; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MUTATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 80051983041     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611796799258     Document Type: Article

References (36)

1. Trevino, J. G.; Summy, J. M.; Gallick, G. E. SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev. Med. Chem. 2006, 6, 681-687. (Pubitemid 43881119)
2. Aligayer, H.; Boyd, D. D.; Heiss, M. M.; Abdalla, E. K.; Curley, S. A.; Gallick, G. E. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002, 94, 344-351. (Pubitemid 34081362)
3. Irby, R. B.; Yeatman, T. J. Role of Src expression and activation in human cancer. Oncogene 2000, 19, 5636-5642.
4. Belsches-Jablonski, A. P.; Biscardi, J. S.; Peavy, D. R.; Tice, D. A.; Romney, D. A.; Parsons, S. J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001, 20, 1465-1475. (Pubitemid 32291197)
5. Ito, H.; Gardner-Thorpe, J.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003, 134, 221-226. (Pubitemid 37070342)
6. Summy, J. M.; Gallick, G. E. Src family kinases in tumor progression and metastasis. Cancer Metastasis 2003, 22, 337-358. (Pubitemid 36791891)
7. Yeatman, T. J. A renaissance for SRC. Nat. Rev. 2004, 4, 470-480.
8. Benati, D.; Baldari, C. T. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr. Med. Chem. 2008, 15, 1154-1165. (Pubitemid 351997805)
9. Sundaramoorthi, R.; Shakespeare, W. C.; Keenan, T. P.; Metcalf, C. A. 3rd; Wang, Y.; Mani, U.; Taylor, M.; Liu, S.; Bohacek, R. S.; Narula, S. S.; Dalgarno, D. C.; van Schravandijk, M. R.; Violette, S. M.; Liou, S.; Adams, S.; Ram, M. K.; Keats, J. A.; Weigele, M.; Sawyer, T. K. Bone-targeted Src kinase inhibitors: novel pyrroloand pyrazolopyrimidine analogues. Bioorg. Med. Chem. Lett. 2003, 13, 3063-3066. (Pubitemid 36993637)
10. Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Brullo, C.; Fossa, P.; Mosti, L.; Menozzi, G.; Carraro, F.; Naldini, A.; Bernini, C.; Manetti, F.; Botta, M. New pyrazolo[3, 4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg. Med. Chem. Lett. 2004, 14, 2511-2517. (Pubitemid 38515694)
11. Ple, P. A.; Green, T. P.; Hennequin, L. F.; Curwen, J.; Fennell, M.; Allen, J.; Lambert-van der Brempt, C.; Costello, G. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J. Med. Chem. 2004, 47, 871-887. (Pubitemid 38176790)
12. Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier, A.; Otterbein, L.; Plé, P. A.; Warin, N.; Costello, G. N-(5-chloro-1, 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl) ethoxy]-5-(tetrahydro-2H- pyran-4-yloxy) quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465-6488. (Pubitemid 44657442)
13. Barrios Sosa, A. C.; Boschelli, D. H.; Wu, B.; Wang, Y.; Golas, J. M. Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor. Bioorg. Med. Chem. Lett. 2005, 15, 1743-1747. (Pubitemid 40312563)
14. Boschelli, D. H.; Wu, B.; Ye, F.; Durutlic, H.; Golas, J. M.; Lucas, J.; Boschelli, F. Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs. Bioorg. Med. Chem. 2008, 16, 405-412.
15. Boschelli, D. H.; Wang, D.; Wang, Y.; Wu, B.; Honores, E. E.; Barrios Sosa, A. C.; Chaudhary, I.; Golas, J.; Lucas, J.; Boschelli, F. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 2924-2927.
16. Dulsat, C.; Mealy, N.; Castaner, R. Saracatinib. Dual Src/ABL kinase inhibitor, Oncolytic. Drugs of Future 2009, 34, 106.
17. Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 2001, 44, 3965-3977. (Pubitemid 33051486)
18. + ALL. Drugs Future 2007, 32, 481.
19. Lawrence, D. S.; Niu, J. Protein kinase inhibitors: the tyrosinespecific protein kinases. Pharmacol. Ther. 1998, 77, 81-114. (Pubitemid 28077909)
20. Posner, I.; Engel, M.; Gazit, A.; Levitzki, A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol. Pharmacol., 1994, 45, 673-683. (Pubitemid 24139194)
21. Agbotounou, W. K.; Levitzki, A.; Jacquemin-Sablon, A.; Pierre, J. Effects of tyrphostins on the activated c-src protein in NIH/3T3 cells. Mol. Pharmacol. 1994, 45, 922-931. (Pubitemid 24155783)
22. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
23. (a) Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Wang, Y.; Zhao, J.; Jia, S.; Herich, J.; Labreque, D.; Storer, R.; Meerovitch, K.; Bouard, D.; Rej, R.; Denis, R.; Blais, C.; Lamothe, S.; Attardo, G.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell-and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group. J. Med. Chem. 2004, 47, 6299-6310; (Pubitemid 39587254)
24. (b) Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Zhao, J.; Jia, S.; Xu, L.; Crogan-Grundy, C.; Denis, R.; Barriault, N.; Vaillancourt, L.; Charron, S.; Dodd, J.; Attardo, G.; Labreque, D.; Lamothe, S.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell-and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7-and 5-, 6-, 8-positions. Bioorg. Med. Chem. Lett. 2005, 15, 4745-4751. (Pubitemid 41354799)
25. Mahmoodi, M.; Aliabadi, A.; Emami, S.; Safavi, M.; Rajabalian, S.; Mohagheghi, M. A.; Khoshzaban, A.; Samzadeh-Kermani, A.; Lamei, N.; Shafiee, A.; Foroumadi, A. Synthesis and in-vitro cytotoxicity of poly-functionalized 4-(2-arylthiazol-4-yl)-4H-chromenes. Arch. Pharm. Chem. Life Sci. 2010, 343, 411-416.
26. Kumar, D.; Buchi Reddy, V.; Kumar, A.; Mandal, D.; Tiwari, R.; Parang, K. Click chemistry inspired one-pot synthesis of 1, 4-disubstituted 1, 2, 3-triazoles and their Src kinase inhibitory activity. Bioorg. Med. Chem. Lett. 2011, 21, 449-452.
27. Sharma, D.; Bhatia, S.; Sharma, R. K.; Tiwari, R.; Olsen, C. E.; Mandal, D.; Lehmann, J.; Parang, K.; Parmar, V. S.; Prasad, A. S. Synthesis, Src kinase inhibitory and anticancer activities of 1-substituted 3-(N-alkyl-N-phenylamino) propane-2-ols. Biochimie 2010, 92, 1164-1172.
28. Tiwari, R.; Brown, A.; Narramaneni, S.; Sub, G.; Parang, K. Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands. Biochimie 2010, 92, 1153-1163.
29. Kumar, A.; Wang, Y.; Lin, X.; Sun, G.; Parang, K. Synthesis and evaluation of 3-phenylpyrazolopyrimidine-peptide conjugates as Src tyrosine kinase inhibitors. ChemMedChem 2007, 2, 1346-1360.
30. Kumar, A.; Ye, G.; Wang, Y.; Lin, X.; Sun, G.; Parang, K. Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogs of CIYKYY as Src tyrosine kinase inhibitors. J. Med. Chem. 2006, 49, 3395-3401. (Pubitemid 43830538)
31. Nam, N. H.; Lee, S.; Ye, G.; Sun, G.; Parang, K. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg. Med. Chem. 2004, 12, 5753-5766. (Pubitemid 39388174)
32. Nam, N.-H.; Ye, G.; Sun, G.; Parang, K. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J. Med. Chem. 2004, 47, 3131-3141. (Pubitemid 38702707)
33. Rao, V. K.; Chhikara, B. S.; Shirazi, A. N.; Tiwari, R.; Parang, K.; Kumar, A. 3-Substitued indoles: One-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities. Bioorg. Med. Chem. Lett. 2011, 21, 3511-3514.
34. Foroumadi, A.; Dehghan, G.; Samzadeh-Kermani, A.; Arabsorkhi, F.; Sorkhi, M.; Shafiee, A.; Abdollahi, M. Synthesis and Antioxidant Activity of Some 2-Amino-4-aryl-3-cyano-7-(dimethylamino)-4H-chromenes. Asian J. Chem. 2007, 19, 1391-1396.
35. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comp. Chem. 1983, 4, 187-217.
36. Budde, R. J.; Ke, S.; Levin, V. A. Activity of pp60C-SRC in 60 different cell lines derived from human tumors. Cancer Biochem. Biophys. 1994, 14, 171-175.